TVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. TVTX is sitting just below near-term resistance (~31.55) after a -2.81% regular-session drop, with no proprietary buy signals today and a key catalyst (FILSPARI/FSGS) pushed out to April 13. With the stock near resistance and event-risk still unresolved, the risk/reward for buying immediately is not attractive; I would hold rather than chase.
Trend/price action: Short-term momentum is improving but not decisively breaking out. The stock closed weaker in the regular session (-2.81%) and is trading ~31.09 post-market. Momentum: MACD histogram is positive (0.167) and expanding, which is a bullish tilt. RSI(6) ~54.9 is neutral, implying no momentum extreme. Moving averages: Converging MAs suggest consolidation/indecision rather than a clear trend. Levels: Pivot ~29.52 is the key near-term support area; immediate resistance is R1 ~31.55 (very close to current price), then R2 ~32.81. With price below R1, upside is capped unless it breaks and holds above ~31.55. Pattern-based forward drift (provided): Similar-pattern stats imply mild downside bias (next month expectation -2.91%), reinforcing that the current level is not an optimal immediate entry.
Intellectia Proprietary Trading Signals
on 2026-02-23 (after hours) could reinforce revenue trajectory ahead of the April FDA date.
Legal overhang: Robbins Geller is investigating potential securities violations/misleading statements, which can pressure sentiment and create headline risk.
Catalyst delay: FDA extension pushes the key FSGS decision to April 13, extending uncertainty and increasing the chance of range-bound trading until clarity.
Technical positioning: Price is just below near-term resistance (~31.55); without a clean breakout, risk of rejection/pullback remains.
Latest reported quarter: 2025/Q3.
Growth: Revenue rose to $164.9M (+162.11% YoY), signaling strong commercial momentum.
Profitability: Net income fell to ~$25.7M (-146.90% YoY) and EPS to ~$0.25 (-135.71% YoY), indicating earnings volatility despite surging revenue.
Margins: Gross margin remained extremely high (99.04%, +1.67% YoY), consistent with a high-margin product profile; the key question is operating leverage/expense trajectory going forward.
Recent tone is mixed but improving on fundamentals.
